Hims & Hers Stock Surges on Growth Outlook and Upgraded Price Target
Hims & Hers Health (HIMS) staged a sharp rebound, rallying more than 9% after revenue guidance and analyst support reignited optimism in...
Quick overview
- Hims & Hers Health experienced a significant rebound, with shares rising over 9% following positive revenue guidance and analyst support.
- The company's stock, which had previously dropped to the $40 range, surged past $45 as investor sentiment improved.
- Analyst support from Deutsche Bank, which raised its price target to $48, contributed to the renewed optimism in the stock.
- Looking ahead, Hims & Hers reaffirmed its revenue expectations for 2025, indicating confidence in long-term growth despite recent challenges.
Hims & Hers Health (HIMS) staged a sharp rebound, rallying more than 9% after revenue guidance and analyst support reignited optimism in the digital health stock.
Market Recovery After Q2 Weakness
After a choppy summer marked by weak Q2 earnings, Hims & Hers Health has found its footing. Shares, which had previously tumbled from above $70 to the $40 range, bounced back strongly today. The move higher comes after the company reassured investors with steady revenue projections, sparking renewed buying interest. By mid-session, HIMS stock surged past $45, signaling improved sentiment across the market.
HIMS Chart Daily – The 200 SMA Held As Support
Analyst Support Strengthens Momentum
The bullish tone was reinforced by Deutsche Bank, which raised its price objective for Hims & Hers to $48. While the bank maintained a “Hold” rating, the adjustment gave investors a clearer indication of upside potential. The combination of stronger guidance and Wall Street recognition helped fuel today’s rally.
Growth Outlook and Strategic Partnerships
Earlier in the year, Hims & Hers stock had captured significant investor attention, climbing above $73 in February amid surging enthusiasm for digital health platforms. That optimism faded as growth-oriented stocks came under pressure, pushing HIMS as low as $24 in April. The company, however, took steps to broaden its offerings, most notably through a partnership with Danish pharmaceutical leader Novo Nordisk (NVO). This collaboration allowed Hims & Hers to provide telemedicine access to Wegovy, a widely popular weight-loss treatment, adding a new driver for future growth.
Updated Forecasts for 2025
Looking ahead, Hims & Hers reaffirmed fiscal year 2025 revenue expectations in the range of $2.3–$2.4 billion, in line with the consensus of $2.35 billion. For Q3, the company projects revenue between $570 million and $590 million and adjusted EBITDA of $60 million to $70 million. Although Q2 earnings per share fell short of forecasts, management stressed confidence in long-term growth, especially in higher-impact specialty care areas.
Conclusion: Signs of Stabilization
After months of volatility, Hims & Hers appears to be regaining market trust. While challenges remain, the combination of steady revenue guidance, analyst recognition, and strategic partnerships suggests the company is positioning itself for a healthier trajectory heading into 2025.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
Save